



Department of Pathology

Te Tari Mātauraka Mate

PRESENTS

Special Seminar:



Professor Jim Lorens

Department of Biomedicine, University of Bergen

The Role of AXL in Cancer Therapy Resistance: Bench to Bedside

Photo: Ingvild Festervoll Møllen

Prof Lorens' research investigates signaling events and metabolism in various phases of tumor development, including tumor growth, drug resistance and metastasis. His group uses multidisciplinary approaches employing biochemistry, cell-based systems, molecular biology, animal models, and collaborations with pharmaceutical industry and clinical research. He has significant translational experience. He founded and is Chief Scientific Officer of BerGenBio, a publicly listed biopharmaceutical company. BerGenBio's AXL inhibitor Bemcentinib (BGB324) is in phase 2 clinical trials as a monotherapy and in combination with immunotherapies, targeted therapies and chemotherapy with trials for multiple hematologic malignancies and solid tumours. AXL is linked to mechanisms of drug resistance and immune escape by tumour cells. The US FDA has granted Fast Track Designation for Bemcentinib for the treatment of elderly patients with relapsed acute myeloid leukaemia (AML).

Prof Lorens is a long-time collaborator of Prof Bruce Baguley and his New Zealand visit is supported by the Maurice Wilkins Centre for Molecular Biodiscovery.

Monday 17 February, 12pm | D'Ath Lecture Theatre, Department of Pathology

More information: otago.ac.nz/dsm-pathology